Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CANCER CELL COVER

​Client:
Staudt, Louis (NIH/NCI)
Project description:
The so-called “Phoenix” Phase III randomized clinical trial evaluated the benefit of adding the BTK inhibitor ibrutinib to standard R-CHOP chemotherapy in patients with newly diagnosed non-GCB DLBCL.
Manuscript title:
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma
Cancer Cell Volume 39, Issue 12p1549-1654
PMID: 34739844
PubMed
Illustrator: Erina He

​​